Service de Pharmacologie Clinique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier A Chenevier, H Mondor, Av Maréchal de Lattre de Tassigny, 94010 Créteil, France.
Fundam Clin Pharmacol. 2011 Jun;25(3):395-404. doi: 10.1111/j.1472-8206.2010.00832.x.
The many clinical trials investigating the effect of various antihypertensive drugs on carotid intima-media thickness (CIMT) produced conflicting results. We used meta-analysis to evaluate CIMT changes and network meta-analysis to rank drugs according to the magnitude of these changes. We identified 31 randomized controlled trials listed in three databases as of January 2008. Using a random-effects model, we found a significant CIMT decrease with antihypertensive drugs compared to placebo (-0.10 [-0.16; -0.04]). Overall effect sizes vs. placebo were significant for angiotensin-converting enzyme (ACE) inhibitors (-0.08 [-0.14; -0.02]), and a trend was found for beta-blockers (-0.09 [-0.19; 0.01]). The data did not allow other direct comparisons vs. placebo. Significant benefits were found for calcium-channel blockers (CCBs) compared to both ACE inhibitors (0.37 [0.20; 0.54]), as well as for angiotensin II receptor blockers (ARBs) compared to beta-blockers (0.42 [0.29; 0.55]). Diuretics were less efficient than CCBs (-0.09 [-0.16; -0.02]). Indirect comparisons with network meta-analysis showed significant effects of CCBs and ARBs vs. placebo (both P < 0.05) and vs. diuretics (both P < 0.001). The CIMT decrease with ACE inhibitors and beta-blockers was greater than with diuretics (both P < 0.05) but was not different from the placebo effect. In subgroup analyses, significant benefits occurred with lower baseline CIMT values and shorter treatment durations but were unrelated to the size of the blood pressure decrease. In conclusion, among antihypertensive drugs, CCBs and ARBs have the greatest effect on CIMT.
许多临床试验研究了各种抗高血压药物对颈动脉内膜中层厚度(CIMT)的影响,结果相互矛盾。我们采用荟萃分析来评估 CIMT 的变化,并采用网络荟萃分析根据这些变化的程度对药物进行排名。我们在三个数据库中确定了截至 2008 年 1 月的 31 项随机对照试验。使用随机效应模型,我们发现与安慰剂相比,抗高血压药物可显著降低 CIMT(-0.10 [-0.16;-0.04])。与安慰剂相比,血管紧张素转换酶(ACE)抑制剂的总体效应大小显著(-0.08 [-0.14;-0.02]),β-受体阻滞剂也有趋势(-0.09 [-0.19;0.01])。数据不允许与安慰剂进行其他直接比较。与 ACE 抑制剂相比,钙通道阻滞剂(CCB)具有显著优势(0.37 [0.20;0.54]),与β受体阻滞剂相比,血管紧张素 II 受体阻滞剂(ARB)也具有显著优势(0.42 [0.29;0.55])。与 CCB 相比,利尿剂效率较低(-0.09 [-0.16;-0.02])。网络荟萃分析的间接比较显示,CCB 和 ARB 与安慰剂相比(均 P < 0.05)和与利尿剂相比(均 P < 0.001)均有显著效果。与 ACE 抑制剂和β受体阻滞剂相比,ACE 抑制剂和β受体阻滞剂的 CIMT 降低幅度大于利尿剂(均 P < 0.05),但与安慰剂的效果无差异。在亚组分析中,较低的基线 CIMT 值和较短的治疗时间与显著的获益相关,但与血压降低的幅度无关。总之,在抗高血压药物中,CCB 和 ARB 对 CIMT 的影响最大。